Onconetix Inc
ONCO
View Detailed Chart
3.200USD
+2.627+457.98%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
883.89KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+457.98%
5 Days
+23.41%
1 Month
-2.96%
6 Months
-79.94%
Year to Date
-58.97%
1 Year
-92.38%
View Detailed Chart
TradingKey Stock Score of Onconetix Inc
Currency: USD Updated: 2026-03-25Key Insights
Onconetix Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Onconetix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Onconetix Inc Highlights
StrengthsRisks
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1294.63% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 815.37K.
Undervalued
The company’s latest PE is -0.18, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 91.66K shares, increasing 40.70% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Onconetix Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Onconetix Inc Info
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Ticker SymbolONCO
CompanyOnconetix Inc
CEOFedasz (Karina M)
Websitehttps://www.onconetix.com/
Related Instruments
-0.68%
-0.88%
+1.69%
-1.35%
+2.19%
+2.89%
+0.72%
+1.38%
-2.13%
+2.21%
-1.38%
+3.26%
+1.89%
+3.52%
+1.15%
0.00%
+2.01%
+0.28%
+0.62%
+0.03%Popular Symbols
252.980
+1.340 (+0.53%)
171.340
-3.860 (-2.20%)
68757.550
-217.660 (-0.32%)
273.280
-27.770 (-9.22%)
2061.500
-0.890 (-0.04%)
372.260
-13.690 (-3.55%)
4413.190
+33.130 (+0.76%)
92.709
-0.613 (-0.66%)
1.154
+0.001 (+0.09%)
159.667
-0.120 (-0.07%)
